Assessing evidence for dietary supplements in clinical practice

The clinical usefulness of a dietary supplement does not depend solely on its ingredient. It requires a defined indication, evidence in humans, an identifiable formulation, safety, and follow-up adapted to each patient.

In summary:

• The recommendation should start from the clinical objective and the patient’s context, not solely from the ingredient listed on the label.
• With probiotics, the evidence may depend on the strain, dose, formulation, and indication studied; it should not be automatically extrapolated between products.
• Safety, interactions, contraindications, and product quality are part of the decision, together with the expected benefit.
• An analysis of gut microbiota can provide context on microbial composition, but it does not by itself demonstrate that a supplement will be effective.

The professional decision should distinguish between a biologically plausible hypothesis and an observed clinical benefit, document the objective, and review the response without replacing clinical assessment.

What is the difference between a promising ingredient and a supplement with clinical utility?

A promising ingredient is based on a biological hypothesis, but a supplement with clinical utility requires results in people, a specific indication, an identifiable formulation, and a reasonable balance between expected benefits and risks for the patient, as well as a decision that can be reviewed during follow-up.

Biological plausibility explains why an ingredient might produce an effect: for example, by modifying a metabolic pathway or interacting with the microbiota. Experimental studies help explore this mechanism, but they do not allow us to assume the same result in people. Nor does an association between an ingredient and a benefit demonstrate that the supplement is the cause.

To assess its applicability, it is useful to check:

• Study population and clinical objective.
• Dose, formulation and duration evaluated.
• Outcomes relevant to that patient.
• Safety and possible interactions.

A microbiota test with a clinical approach can provide context, but it does not turn a hypothesis into a recommendation or replace professional assessment.

How does the evidence for probiotics, prebiotics and other supplements compare?

The evidence cannot be transferred automatically between probiotics, prebiotics and other supplements, because their results may depend on the ingredient, formulation, population studied, dose and clinical objective assessed. For this reason, comparisons should be made product by product and indication by indication.

It is important to distinguish between which microorganisms are present and what activity the microbiota performs. For more information about butyrate, propionate and acetate, see the content on short-chain fatty acids.

What should a healthcare professional review before recommending a supplement?

Before recommending a supplement, it is advisable to confirm that it addresses a specific reason for consultation, define an assessable clinical objective, review the evidence for the ingredient or product, rule out alternative diagnoses, check medication and individual risks, and agree how its continuation or discontinuation will be assessed.

A practical review can follow this order:

• Clinical context: symptoms, medical history, comorbidities, pregnancy, allergies and immunosuppression.
• Indication: measurable objective, differential diagnosis and relevant clinical alternatives.
• Safety: concomitant medication, possible interactions, tolerability and signs that indicate it should be discontinued.
• Product: ingredient, dose, formulation, quality and labelling; distinguish substantiated information from advertising.
• Follow-up: planned duration, variables to be reviewed and criteria for continuing, changing or discontinuing the recommendation.

The decision should be documented and explained to the patient together with the available uncertainty, without presenting a hypothesis as a guaranteed outcome. To integrate analyses into clinical practice, see the access for healthcare professionals.

When can a microbiota analysis provide useful information?

A microbiota analysis can provide information about the microorganisms present in an intestinal sample and help guide clinical questions. However, it cannot on its own confirm whether a food supplement is needed or establish that it will be effective: its interpretation should be considered alongside symptoms, medical history, diet, medication and clinical examination.

Metagenomic sequencing can describe the microbial composition of the sample and help assess whether certain hypotheses warrant further investigation. On its own, it does not establish the cause of a symptom, the presence of a disease or how a person will respond to a supplement.

Knowing which microorganisms are present is not the same as knowing what activity they carry out. Studying metabolites such as butyrate, propionate or acetate requires a functional approach, such as functional metabolomics. The results should be considered alongside the medical history and should not replace professional assessment.

How should follow-up be carried out after recommending it?

Follow-up should assess tolerance and progress towards the defined objective, record adherence and review whether the recommendation should be continued at an agreed time, without interpreting a subjective change as evidence of efficacy. If risks emerge, symptoms worsen or there is no clinically relevant benefit, the recommendation should be reconsidered and other causes investigated.

Before starting, it is useful to document:

• The clinical objective and the variables to be monitored.
• The recommended regimen, adherence and any issues that arise.
• Tolerance, new symptoms and changes in medication.
• The planned time for reassessment and the criteria for continuing or stopping.

Reassessment should consider the patient’s overall progress, not just an isolated perception. If symptoms persist, warning signs appear or the objective is not achieved, the differential diagnosis should be reviewed and referral or additional tests considered. When a microbiota report is available, Sophia can help interpret it, always alongside the clinical history and professional judgement.

Frequently asked questions

Is it necessary to have a microbiota analysis before taking a supplement?

No. A microbiota analysis is not generally required when assessing a dietary supplement. The decision should be based on the reason for consultation, the clinical situation, the available evidence and the product’s safety profile. An analysis may provide context in selected cases, but it does not, on its own, confirm that a supplement is necessary or that it will be effective.

Do all probiotics work for the same symptoms?

No. Probiotics should not be considered equivalent simply because they belong to the same category. Their potential usefulness may depend on the genus, species, strain, formulation, dose, population studied and clinical objective. For this reason, the results associated with one product or indication should not automatically be applied to a different one.

What information on the label should be checked?

It is important to check the full composition, the identification of the microorganisms or ingredients, the stated amount, directions for use, warnings and storage conditions. This information should also be considered in relation to the patient’s clinical situation, medication and medical history. The label provides information about the product, but it does not replace professional assessment.

Can a supplement replace a prescribed treatment?

A dietary supplement should not be used to replace a prescribed treatment without professional advice or to delay a clinical assessment. Its possible inclusion should be considered as part of an individualised plan, taking into account the diagnosis, therapeutic objectives, safety and available alternatives. Any change to medication should be reviewed with the responsible healthcare professional.

How should uncertainty about the evidence be communicated to the patient?

Uncertainty should be communicated by explaining what is known, which aspects remain unclear and how closely the evidence applies to the patient’s situation. It is useful to distinguish a biological hypothesis from a demonstrated clinical outcome, agree on what will be monitored and review the decision if no relevant benefit is observed or tolerability problems arise.

Request professional access to assess microbiota analyses and integrate them into your clinical practice.